Rony Kapoor

639 total citations
15 papers, 237 citations indexed

About

Rony Kapoor is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Rony Kapoor has authored 15 papers receiving a total of 237 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 10 papers in Molecular Biology and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Rony Kapoor's work include Melanoma and MAPK Pathways (9 papers), Cutaneous Melanoma Detection and Management (5 papers) and Cancer Immunotherapy and Biomarkers (5 papers). Rony Kapoor is often cited by papers focused on Melanoma and MAPK Pathways (9 papers), Cutaneous Melanoma Detection and Management (5 papers) and Cancer Immunotherapy and Biomarkers (5 papers). Rony Kapoor collaborates with scholars based in Australia, Switzerland and Singapore. Rony Kapoor's co-authors include Georgina V. Long, Alexander M. Menzies, Louise Emmett, Matteo S. Carlino, Serigne Lo, Aaron C. Tan, Alexander Guminski, Richard A. Scolyer, Robyn P.M. Saw and John F. Thompson and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and Annals of Oncology.

In The Last Decade

Rony Kapoor

13 papers receiving 233 citations

Peers

Rony Kapoor

ONCOL

IMMUN

PRM

RNMI

Patrick Brunhoeber United States

Yuki Muroyama United States

Ming Gu China

Wendy Mao United States

Claire Y. Oh United States

Annie Borch Denmark

Amy Hankin United States

Daniel J. Craig United States

Mikiya Ishihara Japan

Tarsem Moudgil United States

Patrick Brunhoeber United States

Rony Kapoor

109 ×0.6

ONCOL

54 ×0.8

IMMUN

63 ×1.2

30 ×0.6

PRM

39 ×0.8

RNMI

Citations per year, relative to Rony Kapoor Rony Kapoor (= 1×) peers Patrick Brunhoeber

Countries citing papers authored by Rony Kapoor

Since Specialization

Citations

This map shows the geographic impact of Rony Kapoor's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rony Kapoor with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rony Kapoor more than expected).

Fields of papers citing papers by Rony Kapoor

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rony Kapoor. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rony Kapoor. The network helps show where Rony Kapoor may publish in the future.

Co-authorship network of co-authors of Rony Kapoor

This figure shows the co-authorship network connecting the top 25 collaborators of Rony Kapoor. A scholar is included among the top collaborators of Rony Kapoor based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rony Kapoor. Rony Kapoor is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Zhou, Li, Edward Hsiao, Serigne Lo, et al.. (2024). FDG-PET associations with pathological response and survival with neoadjuvant immunotherapy for melanoma.. Journal of Clinical Oncology. 42(16_suppl). 9523–9523.

Gonzalez, Maria, Alexander Christopher Jonathan Van Akkooi, Sydney Ch’ng, et al.. (2024). A phase 2 study to determine the pathological (path) response to neoadjuvant nivolumab (nivo) and relatlimab (rela) in stage I to III resectable Merkel cell carcinoma (Neo-MCC).. Journal of Clinical Oncology. 42(16_suppl). TPS9613–TPS9613.

Long, Georgina V., Matteo S. Carlino, George Au‐Yeung, et al.. (2024). Neoadjuvant pembrolizumab, dabrafenib and trametinib in BRAFV600-mutant resectable melanoma: the randomized phase 2 NeoTrio trial. Nature Medicine. 30(9). 2540–2548. 15 indexed citations

Gonzalez, Maria, Alexander Christopher Jonathan Van Akkooi, Andrew J. Spillane, et al.. (2023). A phase 2 study to determine the pathological (path) response to neoadjuvant nivolumab (nivo) and relatlimab (rela) in high-risk stage II cutaneous melanoma: NeoReNi II.. Journal of Clinical Oncology. 41(16_suppl). TPS9610–TPS9610. 1 indexed citations

Menzies, Alexander M., Robyn P.M. Saw, Serigne Lo, et al.. (2022). Neoadjuvant dabrafenib and trametinib (D+T) for stage III melanoma: Long-term results from the NeoCombi trial.. Journal of Clinical Oncology. 40(16_suppl). 9580–9580. 6 indexed citations

Ch’ng, Sydney, Semra Uyulmaz, Matteo S. Carlino, et al.. (2021). Re-defining the role of surgery in the management of patients with oligometastatic stage IV melanoma in the era of effective systemic therapies. European Journal of Cancer. 153. 8–15. 5 indexed citations

Hong, Angela, Wei Wang, Bi Chen, et al.. (2021). Risk of radiation necrosis after stereotactic radiosurgery for melanoma brain metastasis by anatomical location. Strahlentherapie und Onkologie. 197(12). 1104–1112. 9 indexed citations

Dimitriou, Florentia, Serigne Lo, Aaron C. Tan, et al.. (2021). FDG-PET to predict long-term outcome from anti-PD-1 therapy in metastatic melanoma. Annals of Oncology. 33(1). 99–106. 22 indexed citations

Tan, Aaron C., Louise Emmett, Serigne Lo, et al.. (2018). FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma. Annals of Oncology. 29(10). 2115–2120. 104 indexed citations

10.

Goodwin, Annabel, Rony Kapoor, Robert M. Conway, et al.. (2018). Germline BAP1 -positive patients: the dilemmas of cancer surveillance and a proposed interdisciplinary consensus monitoring strategy. European Journal of Cancer. 92. 48–53. 20 indexed citations

11.

Menzies, Alexander M., Maria Gonzalez, Alex Guminski, et al.. (2017). Phase 2 study of neoadjuvant dabrafenib + trametinib (D+T) for resectable stage IIIB/C BRAF V600 mutant melanoma. Annals of Oncology. 28. v432–v432. 29 indexed citations

12.

Thompson, John F., et al.. (2017). Melanoma patient imaging in the era of effective systemic therapies. European Journal of Surgical Oncology. 43(8). 1517–1527. 8 indexed citations

13.

Menzies, Alexander M., et al.. (2017). Radiological manifestations of immune‐related adverse effects observed in patients with melanoma undergoing immunotherapy. Journal of Medical Imaging and Radiation Oncology. 61(6). 759–766. 5 indexed citations

14.

Kapoor, Rony, et al.. (2006). Clinical Spectrum and Prognosis of Multiple Myeloma in Patients Younger than 30 Years : Is it Different from the Elderly ?. 7 indexed citations

15.

Kapoor, Rony, et al.. (2001). Tc-99m–Labeled RBC Scintigraphy and Splenic Hemangioma. Clinical Nuclear Medicine. 26(12). 1022–1023. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact